Apellis Pharmaceuticals Inc - Company Profile
Powered by
All the data and insights you need on Apellis Pharmaceuticals Inc in one report.
- Save hours of research time and resources with
our up-to-date Apellis Pharmaceuticals Inc Strategy Report
- Understand Apellis Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Apellis Pharmaceuticals Inc (Apellis) is a clinical-stage biopharmaceutical company that focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases through inhibition of the complement system at the level of C3 (central protein). Its pipeline product portfolio includes EMPAVELI pegcetacoplan injection for paroxysmal nocturnal hemoglobinuria disease and SYFOVRE intravitreal pegcetacoplan injection for Geographic Atrophy. Its other products include APL-1030, APL-2006 and Orala Alternative Pathway Inhibitor, among others. The company conducts research on chronic therapy with a C3 inhibitor into clinical trialsIt operates in Australia, Bermuda, the US, Germany, France, Ireland, the Netherlands, Switzerland, the UK nad Cayman Islands. Apellis is headquartered in Waltham, Massachusetts, the US.
Apellis Pharmaceuticals Inc premium industry data and analytics
Products and Services
Products |
---|
EMPAVELI (Pegcetacoplan) Injection: Paroxysmal nocturnal Hemoglobinuria |
SYFOVRE (Intravitreal pegcetacoplan Injection): Geographic Atrophy |
APL-1030 |
XYZ |
XYZ |
XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2023 | Regulatory Approval | In October, the company secured an approval from the U.S. Food and Drug Administration for EMPAVELI Injector. |
2023 | Contracts/Agreements | In March, the company entered into an agreement with Neophth Biotechnology to jointly develop gene therapy research and development projects for retinal degenerative diseases. |
2023 | Regulatory Approval | In February, the company announced that the U.S. Food and Drug Administration approved SYFOVRE for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). |
Competitor Comparison
Key Parameters | Apellis Pharmaceuticals Inc | AstraZeneca Plc | Amneal Pharmaceuticals Inc | CytomX Therapeutics Inc | Aclaris Therapeutics Inc |
---|---|---|---|---|---|
Headquarters | United States of America | United Kingdom | United States of America | United States of America | United States of America |
City | Waltham | Cambridge | Bridgewater | South San Francisco | Wayne |
State/Province | Massachusetts | England | New Jersey | California | Pennsylvania |
No. of Employees | 702 | 89,900 | 7,700 | 120 | 91 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Gerald Chan | Chairman | Executive Board | 2013 | 72 |
Cedric Francois | Director; President; Chief Executive Officer | Executive Board | 2009 | 50 |
Timothy Sullivan | Chief Financial Officer; Treasurer | Senior Management | 2017 | 52 |
Jim Chopas | Vice President; Chief Accounting Officer; Controller | Senior Management | 2021 | 56 |
Karen Lewis | Chief People Officer | Senior Management | 2020 | 51 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward